de Wit M - Vivantes Klinikum | 人才画像

基本信息

Career Trajectory

Bio

No content for now

Research Interests

Papers共 55 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

Analyse Perioperativer Immunvermittelter Nebenwirkungen Neoadjuvant Vorbehandelter NSCLC Patienten*innen

B Kirzinger,C Beushausen,S Sklenar, S Kolacz,M De Wit,S Eggeling

Zentralblatt für Chirurgie - Zeitschrift für Allgemeine, Viszeral-, Thorax- und Gefäßchirurgie 33 Jahrestagung der Deutschen Gesellschaft für Thoraxchirurgie (2024)

Cited0Views0Bibtex

Investigation of cardiac biomarkers and association with clinical course under treatment with a carfilzomib containing quadruplet regimen in high-risk newly diagnosed multiple myeloma patients: results from the correlative program of the GMMG-CONCEPT trial

A. Beitzen-Heineke, L. Guo, A. L. F. Engels,B. Besemer,M. Haenel,M. S. Raab,C. Mann,M. Munder,H. C. Reinhardt,A. Nogai,M. Goerner,Y. D. Ko,M. de Wit,H. Salwender,C. Scheid,U. Graeven,R. Peceny,P. Staib,A. Dieing,H. Goldschmidt, C. Bokemeyer,T. Zeller,R. Twerenbold,D. Westermann,K. Weisel, L. B. Leypoldt

ONCOLOGY RESEARCH AND TREATMENT (2023): 32-33

Cited0Views0Bibtex

Testing for and frequency of EGFR and ALK alterations in patients with early and locally advanced non-small cell lung cancer in Germany. Results from the prospective German Registry CRISP (AIO-TRK-0315)

W. E. E. Eberhardt, M. Thomas,M. Stuschke,M. de Wit,B. Seese,L. Spring,A. Andres-Pons,M. Janicke, O. Vahtrick,P. Ludwig,A. Hipper,P. Hoffknecht,E. von der Heyde,M. Sebastian,A. Groeschel,B. Passlick,F. Griesinger

ONCOLOGY RESEARCH AND TREATMENT (2023): 10-11

Cited0Views0Bibtex

Influenza vaccination rates in the risk group of oncological patients - prospective data from the Berlin metropolitan region

T. Kiderlen, K. Trostdorf,M. Reinwald,M. De Wit

ONCOLOGY RESEARCH AND TREATMENT（2022）

Cited0Views0Bibtex

1301P Sequential Therapy of Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) after Failure of Gemcitabine Plus Nab-Paclitaxel with Either 5-Fu/folinic Acid (5FU/LV) Plus Irinotecan (FOLFIRI) Followed by 5FU/LV Plus Oxaliplatin (OFF) or the Reverse Sequence: the PANTHEON Trial (AIO PAK 0116)

D. P. Modest,V. Heinemann,P. Schuett,S. Angermeier, M. Haberkorn,O. Waidmann,U. Graeven, K. Wille,V. Kunzmann,L. Henze, C. Constantin,M. De Wit,C. Denzlinger,A. Kurreck,A. H. S. Alig,A. Stahler,U. Pelzer,S. Stintzing,H. Oettle

Annals of oncology (2022): S1139-S1139

Cited0Views0Bibtex

PD-L1-Expression Im Primärtumor Vs. Metastase in Proben Der Phase-III-Studie MYSTIC Bei 1St-Line Metastasiertem NSCLC

T Wehler,N Reinmuth,AM Boothman,BC Cho,KH Lee,A Luft,JC Ahn,M Scott,J Whiteley,J Walker,V Karwe,P Mukhopadhyay,P Thiyagarajah,U Scheuring,N Rizvi,M de Wit

Pneumologie（2020）

Cited0Views0Bibtex

PD-L1-Expression in the Primary Tumor versus Metastasis in Samples of the Phase-III-Study MYSTIC of Patients with 1st-Line metastatic NSCLC

T. Wehler,N. Reinmuth,A. M. Boothman,B. C. Cho,K. H. Lee,A. Luft,J. C. Ahn,M. Scott,J. Whiteley,J. Walker,V Karwe,P. Mukhopadhyay,P. Thiyagarajah,U. Scheuring,N. Rizvi,M. de Wit

PNEUMOLOGIE（2020）

Cited0Views0Bibtex

NIS OPTIMOB: First Results of Real-World Data on Mobilization and Collection of Hematopoietic Stem and Progenitor Cells in Patients with Multiple Myeloma and Lymphoma in Germany

M. Bittrich,K. Movassaghi,V. Vucinic,M. Grube,K. Kriegsmann, H. A. Duerk,C. Kunz,D. Wehler,B. Metzner,M. Hentrich,M. de Wit,M. Schmidt-Hieber,A. Humpe,N. Kroeger

ONCOLOGY RESEARCH AND TREATMENTno. SUPPL 4 (2020): 242-243

Cited0Views0Bibtex

PD-L1 Expression in Primary Tumour vs Metastatic Samples in The Phase 3 MYSTiC Study in First-Line Metastatic (m) NSCLC

T. Wehler,N. Reinmuth,A. -M Boothman,B. C. Cho,K. H. Lee,A. Luft,M. -J. Ahn,M. Scott,J. Whiteley,J. Walker,V. Karwe,P. Mukhopadhyay,P. Thiyagarajah,U. Scheuring,N. Rizvi,M. de Wit

ONCOLOGY RESEARCH AND TREATMENT（2020）

Cited0Views0Bibtex

Author Statistics

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn